SPAK and WNK kinases: A new target for blood pressure treatment?

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 1, 2011, Pages 16-22

  Glover, Mark ^a   O'Shaughnessy, Kevin M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Blood pressure; Monogenic hypertension; Salt homeostasis; Sodium chloride cotransporter; SPAK; STK39; Thiazides; WNK kinases

Indexed keywords

PROTEIN; PROTEIN KINASE WNK1; PROTEIN KINASE WNK4; PROTEIN SPAK; SODIUM CHLORIDE COTRANSPORTER; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE REGULATION; GENETIC ASSOCIATION; GORDON SYNDROME; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY TUBULE ABSORPTION; NEPHRON; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; REGULATORY MECHANISM; SALT WASTING; SODIUM ABSORPTION;

ANIMALS; ARTHROGRYPOSIS; BLOOD PRESSURE; CLEFT PALATE; CLUBFOOT; HAND DEFORMITIES, CONGENITAL; HUMANS; HYPERTENSION; PROTEIN-SERINE-THREONINE KINASES; SODIUM CHLORIDE SYMPORTERS; TRANSCRIPTION FACTORS;

EID: 79851508036     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834132bc     Document Type: Article

References (55)

1. World Health Organization. Global strategy on diet, physical activity and health. Cardiovascular disease: prevention and control; 2009. http://www.who.int/dietphysicalactivity/publications/facts/cvd/en/2009.
2. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004; 18:139-185. (Pubitemid 38425770)
3. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-678.
4. Kahle KT, Ring AM, Lifton RP. Molecular physiology of the WNK kinases. Annu Rev Physiol 2008; 70:329-355. (Pubitemid 351738183)
5. Bobulescu IA, Moe OW. Luminal Na(+)/H(+) exchange in the proximal tubule. Pflugers Arch 2009; 458:5-21.
6. Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 1966; 79:221-235.
7. Gordon RD, Geddes RA, Pawsey CG, O'Halloran MW. Hypertension and severe hyperkalemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 1970; 19:287-294.
8. Canessa CM, Horisberger JD, Rossier BC. Epithelial sodium channel related to proteins involved in neurodegeneration. Nature 1993; 361:467-470. (Pubitemid 23050138)
9. Canessa CM, Schild L, Buell G, et al. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 1994; 367:463-467. (Pubitemid 24046048)
10. Liddle GW, Bledsoe T, Coppage WS Jr. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 1963; 76:199-213.
11. Geller D, Farahi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289:119-123. (Pubitemid 30463305)
12. Mune T, Rogerson F, Nikkila H, et al. Human hypertension caused by mutations in the kidney isozyme of 11B hydroxysteroid dehydrogenase. Nat Genet 1995; 10:394-399.
13. Gordon RD, Hodsman GP. The syndrome of hypertension and hyperkalaemia without renal failure: long term correction by thiazide diuretic. Scott Med J 1986; 31:43-44. (Pubitemid 16131291)
14. Wayne VS, Stockigt JR, Jennings GL. Treatment of mineralocorticoid- resistant renal hyperkalaemia with hypertension (type II hyperaldosteronism). Aust N Z J Med 1986; 16:221-223. (Pubitemid 17184773)
15. Lee MR, Ball SG, Thomas TH, Morgan DB. Hypertension and hyperkalaemia responding to bendrofluazide. Q J Med 1979; 190:245-258. (Pubitemid 9247852)
16. Disse-Nicodeme S, Desitter I, Fiquet-Kempf B, et al. Genetic heterogeneity of familial hyperkalaemic hypertension. J Hypertens 2001; 19:1957-1964. (Pubitemid 33035800)
17. Disse-Nicodeme S, Achard JM, Desitter I, et al. A new locus on chromosome 12p13.3 for pseudohypoaldosteronism type II, an autosomal dominant form of hypertension. Am J Hum Genet 2000; 67:302-310. (Pubitemid 30616737)
18. Mansfield TA, Simon DB, Farfel Z, et al. Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21. Nat Genet 1997; 16:202-205. (Pubitemid 27240623)
19. Riveira-Munoz E, Chang Q, Bindels RJ, Devuyst O. Gitelman's syndrome: towards genotype-phenotype correlations? Pediatr Nephrol 2007; 22:326-332. (Pubitemid 46766753)
20. Riveira-Munoz E, Chang Q, Godefroid N, et al. Transcriptional and functional analyses of SLC1 2A3 mutations: new clues for the pathogenesis of Gitelman syndrome. J Am Soc Nephrol 2007; 18:1271-1283. (Pubitemid 46536913)
21. Cope G, Golbang A, O'Shaughnessy KM. WNK kinases and the control of blood pressure. Pharmacol Ther 2005; 106:221-231. (Pubitemid 40603866)
22. Glover M, Zuber AM, O'Shaughnessy KM. Renal and brain isoforms of WNK3 have opposite effects on NCCT expression. J Am Soc Nephrol 2009; 20:1314-1322.
23. Subramanya AR, Liu J, Ellison DH, et al. WNK4 diverts the thiazide-sensitive NaCl cotransporter to the lysosome and stimulates AP-3 interaction. J Biol Chem 2009; 284:18471-18480.
24. Wilson FH, Kahle KT, Sabath E, et al. Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wildtype but not mutant WNK4. Proc Natl Acad Sci U S A 2003; 100:680-684. (Pubitemid 36126112)
25. Golbang AP, Cope G, Hamad A, et al. Regulation of the expression of the Na/ Cl cotransporter by WNK4 and WNK1: evidence that accelerated dynamindependent endocytosis is not involved. Am J Physiol Renal Physiol 2006; 291:F1369-F1376. (Pubitemid 44887251)
26. Delaloy C, Lu J, Houot AM, et al. Multiple promoters in the WNK1 gene: one controls expression of a kidney-specific kinase-defective isoform. Mol Cell Biol 2003; 23:9208-9221. (Pubitemid 37499808)
27. Rinehart J, Kahle KT, Delos Heros P, et al. WNK3 kinase is a positiveregulator of NKCC2 and NCC, renal cation-Cl- cotransporters required for normal blood pressure homeostasis. Proc Natl Acad Sci U S A 2005; 102:16777-16782. (Pubitemid 41688853)
28. Qiao Y, Liu X, Harvard C, et al. Autism-associated familial microdeletion of Xp11.22. Clin Genet 2008; 1:1-11.
29. Pacheco-Alvarez D, Cristobal PS, Meade P, et al. The Na+:Cl- cotransporter is activated and phosphorylated at the amino-terminal domain upon intracellular chloride depletion. J Biol Chem 2006; 281:28755-28763. (Pubitemid 44507018)
30. Lin SH, Shiang JC, Huang CC, et al. Phenotype and genotype analysis in Chinese patients with Gitelman's syndrome. J Clin Endocrinol Metab 2005; 90:2500-2507.
31. Gagnon KB, England R, Delpire E. Volume sensitivity of cation-Cl- cotransporters is modulated by the interaction of two kinases: Ste20-related prolinealanine-rich kinase and WNK4. Am J Physiol Cell Physiol 2006; 290:C134-C142.
32. Golbang AP, Murthy M, Hamad A, et al. A new kindred with pseudohypoal-dosteronism type II and a novel mutation (564D>H) in the acidic motif of the WNK4 gene. Hypertension 2005; 46:295-300. (Pubitemid 41099160)
33. Gagnon K, England R, Delpire E. Characterization of SPAK and OSR1, regulatory kinases of the Na-K-2Cl cotransporter. Mol Cell Biol 2006; 26:689-698. (Pubitemid 43089779)
34. Richardson C, Alessi DR. The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway. J Cell Sci 2008; 121:3293-3304.
35. Delpire E, Gagnon KB. SPAK and OSR1: STE20 kinases involved in the regulation of ion homoeostasis and volume control in mammalian cells. Biochem J 2008; 409:321-331. (Pubitemid 351184951)
36. Johnston AM, Naselli G, Gonez LJ, et al. SPAK, a STE20/SPS1-related kinase that activates the p38 pathway. Oncogene 2000; 19:4290-4297.
37. Richardson C, Rafiqi FH, Karlsson HK, et al. Activation of the thiazidesensitive Na+-Cl- cotransporter by the WNK-regulated kinases SPAK and OSR1. J Cell Sci 2008; 121:675-684. (Pubitemid 351524166)
38. Dowd B, Forbush B. PASK (proline-alanine-rich STE20-related kinase), a regulatory kinase of the Na-K-Cl cotransporter (NKCC1). J Biol Chem 2003; 278:27347-27353. (Pubitemid 36899915)
39. Piechotta K, Garbarini N, England R, Delpire E. Characterization of the interaction of the stress kinase SPAK with the Na+-K+-2Cl- cotransporter in the nervous system: evidence for a scaffolding role of the kinase. J Biol Chem 2003; 278:52848-52856. (Pubitemid 38035884)
40. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002; 298:1912-1934. (Pubitemid 35425239)
41. Vitari AC, Thastrup J, Rafiqi FH, et al. Functional interactions of the SPAK/ OSR1 kinases with their upstream activator WNK1 and downstream substrate NKCC1. Biochem J 2006; 397:223-231. (Pubitemid 44032854)
42. Vitari AC, Deak M, Morrice NA, Alessi DR. The WNK1 and WNK4 protein kinases that are mutated in Gordon's hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases. Biochem J 2005; 391:17-24. (Pubitemid 41445471)
43. Delpire E, Gagnon KBE. Genome-wide analysis of SPAK/OSR1 binding motifs. Physiol Genomics 2007; 28:223-231. (Pubitemid 46702009)
44. Villa F, Goebel J, Rafiqi FH, et al. Structural insights into the recognition of substrates and activators by the OSR1 kinase. EMBO Rep 2007; 8:839-845. (Pubitemid 350001427)
45. Moriguchi T, Urushiyama S, Hisamoto N, et al. WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters via the STE20-related kinases, SPAK and OSR1. J Biol Chem 2005; 280:42685-42693. (Pubitemid 43049227)
46. Gagnon KB, England R, Diehl L, Delpire E. Apoptosis-associated tyrosine kinase scaffolding of protein phosphatase 1 and SPAK reveals a novel pathway for Na-K-2C1 cotransporter regulation. Am J Physiol Cell Physiol 2007; 292:C1809-C1815. (Pubitemid 47080541)
47. Ponce-Coria J, San-Cristobal P, Kahle KT, et al. Regulation of NKCC2 by a chloride-sensing mechanism involving the WNK3 and SPAK kinases. Proc Natl Acad Sci U S A 2008; 105:8458-8463. (Pubitemid 351904778)
48. Wang Y, O'Connell JR, McArdle PF, et al. From the cover: whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci U S A 2009; 106:226-231.
49. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288:2981-2997.
50. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol 2008; 155:1066-1075.
51. Rafiqi FH, Zuber AM, Glover M, et al. Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Mol Med 2010; 2:63-75.
52. Zabrowicz BP, Abuin A, Ramirez-Solis R, et al. WNK1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci U S A 2003; 100:14109-14114. (Pubitemid 37499199)
53. Chiga M, Rai T, Yang SS, et al. Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone. Kidney Int 2008; 74:1403-1409.
54. Wang Y, O'Connell JR, McArdle PF, et al. Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci USA 2009; 106:226-231.
55. Ji W, Foo NJ, O'Roak BJ, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008; 40:592-599. (Pubitemid 351601207)